The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multi-center retrospective cohort study of patients with mCRPC who received lutetium Lu177 vipivotide tetraxetan.
 
Kunal Desai
Stock and Other Ownership Interests - Co-D Therapeutics
Consulting or Advisory Role - Agent Capital; Sorrento Therapeutics
 
Kerry Roe Schaffer
Honoraria - MJH Live Events
Consulting or Advisory Role - Bayer; Bayer; Janssen Biotech; Sanofi; Sanofi
Research Funding - Tempus (Inst)
 
Katy Beckermann
Consulting or Advisory Role - Alpine Immune Sciences; Aravive; AstraZeneca; AVEO; Bristol-Myers Squibb; Exelixis; Merck; Sanofi; Seagen
Research Funding - Aravive (Inst); ArsenalBio (Inst); Bristol-Myers Squibb; Merck Sharp & Dohme; Pionyr (Inst)
 
Gary Smith
Research Funding - GE Healthcare (Inst)
Travel, Accommodations, Expenses - GE Healthcare
 
Kristin Kathleen Ancell
No Relationships to Disclose
 
Meghan Catenacci
No Relationships to Disclose
 
Daniel Appelbaum
Consulting or Advisory Role - Novartis
Speakers' Bureau - Lantheus Medical Imaging
 
Akash Patnaik
Stock and Other Ownership Interests - Gilead Sciences; Infinity Pharmaceuticals; Merck; Merck
Honoraria - Medscape; Prime Oncology
Consulting or Advisory Role - Curio Science; Exelixis; Gerson Lehrman Group; Guidepoint Pharmacy
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Laekna Health Care (Inst); Progenics (Inst); Xencor (Inst); Zenith Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Exelixis; Prime Oncology
 
Jonathan Trujillo
Travel, Accommodations, Expenses - DAVA Oncology
 
Walter Michael Stadler
Leadership - EMA Wellness
Stock and Other Ownership Interests - Fortress Biotech
Consulting or Advisory Role - AstraZeneca; Bayer; Calico; CVS Caremark; Merck; Pfizer; Treadwell Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Seagen (I); Tesaro (Inst); X4 Pharma (Inst); Xencor (Inst)
Expert Testimony - Apotex; Sandoz
Other Relationship - American Cancer Society; UpToDate
 
Brian I. Rini
Leadership - MashupMD; MJH Life Sciences
Stock and Other Ownership Interests - PTC Therapeutics
Consulting or Advisory Role - Alkermes; Aravive; Arrowhead Pharmaceuticals; Athenex; AVEO; Bristol-Myers Squibb; Corvus Pharmaceuticals; Debiopharm Group; Eisai; EUSA Pharma; Genentech; HiberCell; Merck; NiKang Therapeutics; Pfizer; Surface Oncology
Research Funding - ADC Therapeutics (Inst); Adela (Inst); Aravive (Inst); Arcus Biosciences (Inst); Arrowhead Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); Dracen (Inst); Dragonfly Therapeutics (Inst); Exelixis (Inst); Gilead Sciences (Inst); HiberCell (Inst); Incyte (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Pionyr (Inst); Point Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst); Stata (Inst); Surface Oncology (Inst); Vasgene Therapeutics (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Pfizer
 
Russell Zelig Szmulewitz
Honoraria - Astellas Pharma; Pfizer/Astellas
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Eisai; Exelixis; Janssen Oncology; Merck; Novartis; Pfizer; Sanofi
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Harpoon therapeutics (Inst); Janssen Oncology (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); Plexxikon (Inst); Progenics (Inst)
Patents, Royalties, Other Intellectual Property - Patent licensed by University of Chicago of which I am co-inventor to Corcept Therapeutics for combination AR/GR inhibition in prostate cancer
Travel, Accommodations, Expenses - Corcept Therapeutics